English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Small molecule antagonists of NAADP-induced Ca2+ release in T-lymphocytes suggest potential therapeutic agents for autoimmune disease

Zhang, B., Watt, J. M., Cordiglieri, C., Dammermann, W., Mahon, M. F., Flügel, A., et al. (2018). Small molecule antagonists of NAADP-induced Ca2+ release in T-lymphocytes suggest potential therapeutic agents for autoimmune disease. Scientific Reports, 8: 16775. doi:10.1038/s41598-018-34917-3.

Item is

Files

show Files
hide Files
:
s41598-018-34917-3.pdf (Publisher version), 3MB
Name:
s41598-018-34917-3.pdf
Description:
-
OA-Status:
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
:
41598_2018_34917_MOESM1_ESM.doc (Supplementary material), 5MB
Name:
41598_2018_34917_MOESM1_ESM.doc
Description:
-
OA-Status:
Visibility:
Public
MIME-Type / Checksum:
application/msword / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Zhang, Bo, Author
Watt, Joanna M., Author
Cordiglieri, Chiara1, Author           
Dammermann, Werner, Author
Mahon, Mary F., Author
Flügel, Alexander1, Author           
Guse, Andreas H., Author
Potter, Barry V. L., Author
Affiliations:
1Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society, ou_1113547              

Content

show
hide
Free keywords: ADENINE-DINUCLEOTIDE PHOSPHATE; TYPE-1 RYANODINE RECEPTOR; NICOTINIC-ACID; MULTIPLE-SCLEROSIS; CHEMICAL-SYNTHESIS; CALCIUM; CELLS; HOMEOSTASIS; RIBOSE; TOOLScience & Technology - Other Topics;
 Abstract: Nicotinic acid adenine dinucleotide phosphate (NAADP) is the most potent Ca2+-releasing second messenger known to date, but the precise NAADP/Ca2+ signalling mechanisms are still controversial. We report the synthesis of small-molecule inhibitors of NAADP-induced Ca2+ release based upon the nicotinic acid motif. Alkylation of nicotinic acid with a series of bromoacetamides generated a diverse compound library. However, many members were only weakly active or had poor physicochemical properties. Structural optimisation produced the best inhibitors that interact specifically with the NAADP/Ca2+ release mechanism, having no effect on Ca2+ mobilized by the other well-known second messengers o-myo-inositol 1,4,5-trisphosphate [Ins(1,4,5)P-3] or cyclic adenosine 5'-diphospho-ribose (cADPR). Lead compound (2) was an efficient antagonist of NAADP-evoked Ca2+ release in vitro in intact T lymphocytes and ameliorated clinical disease in vivo in a rat experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis. Compound (3) (also known as BZ194) was synthesized as its bromide salt, confirmed by crystallography, and was more membrane permeant than 2. The corresponding zwitterion (3a), was also prepared and studied by crystallography, but 3 had more desirable physicochemical properties. 3 Is potent in vitro and in vivo and has found widespread use as a tool to modulate NAADP effects in autoimmunity and cardiovascular applications. Taken together, data suggest that the NAADP/Ca2+ signalling mechanism may serve as a potential target for T cell- or cardiomyocyte-related diseases such as multiple sclerosis or arrhythmia. Further modification of these lead compounds may potentially result in drug candidates of clinical use.

Details

show
hide
Language(s): eng - English
 Dates: 2018-11-13
 Publication Status: Issued
 Pages: 17
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Scientific Reports
  Abbreviation : Sci. Rep.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: London, UK : Nature Publishing Group
Pages: - Volume / Issue: 8 Sequence Number: 16775 Start / End Page: - Identifier: ISSN: 2045-2322
CoNE: https://pure.mpg.de/cone/journals/resource/2045-2322